Takeda Pharmaceutical Acquires Intellikine for $310,000,000

  • Feed Type
  • Date
  • Company Name
  • Mailing Address
    10931 N. Torrey Pines Rd. La Jolla, CA 92037
  • Company Description
    Intellikine is a leader in the discovery and development of novel, small molecule therapies targeting the PI3K/Akt/mTOR pathway.
  • Website
  • Transaction Type
  • Transaction Amount
  • Transaction Round
  • Proceeds Purposes
  • M&A Terms
    Under the agreement, Takeda America Holdings will acquire Intellikine for $190 million upfront and up to $120 million in additional potential clinical development milestone payments.

Trending on Xconomy